View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Credit Morning 05/02/2024

BBVA proposes merging with Banco Sabadell to create a European leaderUnited Group: e& has considered a potential acquisition of United Group (Bloomberg)>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 02/05/2024

BBVA propose à Sabadell une fusion afin de créer un leader européenUnited Group : e& envisagerait une possible acquisition de United Group (Bloomberg)>...

Jean Danjou ... (+3)
  • Jean Danjou
  • Oliver Metzger
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2024

Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Q1 2024 results beat expectations, reassuring outlook – recomme...

>Upstream: solid growth profile underpinned by discoveries in Namibia - Adjusted EBITDA for upstream activities totalled € 591m in Q1, 9% above expectations. The group is guiding for divisional EBITDA of € 2.1bn for 2024, which seems fairly conservative, in our view, and output >115 kboe/d, in line with our expectations. This output should increase by over 30% (+40 kboe/d) with the start-up of Bacalhau in Brazil at end-2025 and which should reach its plateau in 202...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Résultats T1 supérieurs aux attentes, outlook rassurant. Recomm...

>Upstream : un profil de croissance solide renforcé par les découvertes en Namibie - L’EBITDA T1 2024 ajusté de l’Upstream est ressorti à 591 M€ et 9% au-dessus des attentes. Le groupe guide sur un EBITDA 2024 de la division à 2.1 Md€ qui nous parait assez conservateur et une production >115 kbep/j en ligne avec nos attentes. Cette production devrait croitre de de plus de 30% (+40 kbep/j) avec le démarrage de Bacalhau au Brésil fin 2025 qui devrait atteindre son pl...

Jerôme Bodin
  • Jerôme Bodin

TF1 : Q1 in line - Outlook for the full year still solid

>Solid Q1 advertising trend driven by the success of TF1+ - On Tuesday, TF1 published its Q1 2024 results, which were followed by a conference call. They were in line with our forecasts for EBITA at € 37.3m (our forecast was € 37.5m). The Q1 advertising trend was solid, notably with a very good performance delivered by TF1+. This was an atypical quarter and marked by an increase in costs. The comparison base was notably relatively unfavourable for programming costs an...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Q1 2024 results: strong beat to consensus with robust cashflow

>Q1 2024: 12% beat on EBITDA, 23% for EBIT and 28% for NI - GALP has just released its Q1 2024 results with EBITDA of € 974m, 12% above the consensus and 14% above our estimates. EBIT came in at € 776m (up 88.8% q-o-q), 23.4% above the consensus. Adjusted net income was € 337m (+18.7% q-o-q) and 28.6% above the consensus. Robust results supported by refining - Upstream: adjusted EBITDA was € 591m (vs € 599m in Q4), 9% above the consensus with lower ...

Jerôme Bodin
  • Jerôme Bodin

TF1 : T1 conforme – Perspectives toujours solides sur l’ensemble de l’...

>Tendance publicitaire T1 solide tirée par le succès de TF1+ - TF1 a publié mardi ses résultats du T1 2024 et a tenu sa conférence téléphonique dans la foulée. Ils sont ressortis en ligne avec nos attentes avec un EBITA de 37,3 M€ alors que nous tablions sur 37,5 M€. La tendance publicitaire a été solide au T1 avec, notamment, une très bonne performance de TF1+. Ce trimestre est atypique et marqué par une hausse des coûts. L’effet de base était notamment peu favorable...

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

 PRESS RELEASE

Communiqué de presse : Des données de vie réelle concernant Beyfortus ...

Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Anglo American plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Anglo American plc 01-May-2024 / 14:43 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s...

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

 PRESS RELEASE

Press Release: Annual General Meeting of April 30, 2024

Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...

 PRESS RELEASE

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement interviendra le 15 mai 2024Composition du Conseil d’administration : renouvellement de deux administrateurs et nomination de trois nouveaux administrateurs indépendants Paris, le 30 avril 2024. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2024, sous la présidence de Frédéric ...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Anglo American plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Anglo American plc 30-Apr-2024 / 14:23 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s...

Carole Braudeau
  • Carole Braudeau

Credit Morning 04/30/2024

Iliad Holding plans to issue new bonds to fund the investment in Tele2 and a tender on Iliad Holding 2026 notesIsabel Marant: well preserved liquidity but further deep fall in the wholesale order bookVerisure markets new bonds with two special covenants linked to a potential IPOBUT/Mobilux: new bond offering with the inclusion of Conforama into the scope>...

Michael B. Schäfer
  • Michael B. Schäfer

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/30/2024

BHP's bid for Anglo American has confirmed interest from miners in copper in the context of increasingly challenged production and difficulties in fully completing projects. Anglo’s (Neutral) prospects in copper are now better valued and this is also the case for BHP (Neutral vs Underperform) although not so for Rio Tinto (Outperform vs Neutral). Downstream, Nexans and Montana Aerospace are our Top Picks (Outperform) vs Aurubis, Rexel and Prysmian (Neutral). - ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch